A clinical trial found that the cholesterol drug Tredaptive increased the rate of side effects such as bleeding and infections, while failing in its ostensible purpose of reducing stroke, heart attack, death or the need for surgery in patients with vascular disease.
According to a Bloomberg report, researchers presented the study of 25,673 patients at the American College of Cardiology meeting in San Francisco.
Tredaptive’s manufacturer, Merck, has suffered from other recent ...
continue reading...